A new era in multiple sclerosis

Referencing Ipsos’ syndicated MS Therapy Monitor data, we explore the impact of the anti-CD20s since their availability – specifically, where they are being used, how they are being used, and neurologists’ perceptions of them.

Momentum continues to build in the use of high-efficacy, disease modifying therapies (DMTs) as a first choice for treating multiple sclerosis. How is this being influenced by the availability of anti-CD20s, a new class of DMT? Will future new therapy classes change the paradigm even further?

In a follow-up to Ipsos’ 2019 point of view, Shifting Paradigms: High-efficacy Therapies in MS Treatment, we use Ipsos’ syndicated MS Therapy Monitor data to explore the impact of the anti-CD20s since their availability – specifically, where they are being used, how they are being used, and neurologists’ perceptions of them.

We also offer a forward-looking view of the potential impact on disease progression of anti-CD20s and other new therapy classes, such as BTK inhibitors.

Download the full paper

Consumer & Shopper